IP Library Granted Patent US 10,758,576
Granted Patent B2
US 10,758,576 · App. 16/056,146 · Granted Sep 1, 2020

Soft tissue repair and regeneration using postpartum-derived cells and cell products

Inventors: Laura J. Brown (Hamilton Square, NJ); Alexander M. Harmon (Clinton, NJ); Anna Gosiewska (Skillman, NJ)
Assignee: DePuy Synthes Products, Inc.
A61K35/51A61K35/50A61K38/18A61K38/185A61K38/1808A61K38/1825A61K38/1833A61K38/1841A61K38/1858A61K38/1866A61K38/1891A61K38/19A61K38/204A61K38/2053A61K38/27C12N5/0605C12N5/0606C12N5/0607A61K35/12C12N2500/32C12N2500/34C12N2500/44C12N2500/90C12N2500/95C12N2501/12C12N2501/21C12N2501/23C12N2502/02C12N2506/02C12N2506/03C12N2509/00C12N2533/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,758,576
App. No.
16/056,146
Granted
Sep 1, 2020
Kind
B2
Abstract

Cells derived from postpartum tissue and products thereof having the potential to support cells of and/or differentiate to cells of a soft tissue lineage, and methods of preparation and use of those postpartum tissue-derived cells, are provided by the invention. The invention also provides methods for the use of such postpartum-derived cells and products related thereto in therapies for conditions of soft tissue.

Claims (28)

1. A method of stimulating cell infiltration in a soft tissue defect in a subject, said method comprising

i) placing isolated umbilical cord tissue-derived cells, or isolated umbilical cord tissue-derived cells that are expanded in culture, onto a scaffold, thereby yielding a scaffold comprising umbilical cord tissue-derived cells; and

ii) administering the scaffold comprising the umbilical cord tissue-derived cells to the soft tissue defect;

wherein the umbilical cord tissue-derived cells are isolated from human umbilical cord tissue substantially free of blood, are capable of self-renewal and expansion in culture, have the potential to differentiate, and have the following characteristics:

a) production of CD10, CD13, CD44, CD73, CD90and HLA-A,B,C;

b) lack of production of CD31, CD34, CD45, CD117, CD141, and HLA-DR, HLA-DP, and HLA-DQ;

c) secrete MCP-1, IL-6, IL-8, GCP-2, HGF, KGF, FGF, HB-EGF, BDNF, TPO, MIP1b, RANTES, and TIMP1; and

d) increased expression of endogenous genes encoding interleukin 8 and reticulon 1 relative to endogenous expression of interleukin 8 and reticulon 1 in a human cell that is a fibroblast, a mesenchymal stem cell, or an ileac crest bone marrow cell,

and wherein the scaffold comprising the umbilical cord tissue-derived cells stimulates cell infiltration into the soft tissue defect.

2. The method of claim 1 , wherein the umbilical cord tissue-derived cells do not secrete SDF-1alpha, TGF-beta2, ANG2, PDGFbb, MIP1a, and VEGF.

3. The method of claim 1 , wherein the method further achieves at least one of tissue repair, tissue reconstruction, tissue bulking, cosmetic treatment, tissue augmentation, and tissue sealing.

4. The method of claim 1 , wherein the soft tissue comprises blood vessels.

5. The method of claim 1 , wherein the step of administering comprises implanting, injecting, or engrafting the scaffold.

6. The method of claim 1 , wherein the method comprises placing isolated umbilical cord tissue-derived cells onto a scaffold.

7. The method of claim 1 , wherein the method comprises placing isolated umbilical cord tissue-derived cells that are expanded in culture onto a scaffold.

8. The method of claim 1 , wherein the scaffold is flat, tubular, or multilayered.

9. The method of claim 1 , wherein the scaffold comprises a nonwoven mat, a porous foam, a suture, or a hydrogel.

10. A method of stimulating cell infiltration in a soft tissue defect in a subject comprising administering a scaffold comprising umbilical cord tissue-derived cells to the soft tissue defect, wherein the umbilical cord tissue-derived cells are isolated from human umbilical cord tissue substantially free of blood, are capable of self-renewal and expansion in culture, have the potential to differentiate, and have the following characteristics:

a) production of CD10, CD13, CD44, CD73, CD90, and HLA-A,B,C;

b) lack of production of CD31, CD34, CD45, CD117, CD141, and HLA-DR, HLA-DP, and HLA-DQ;

c) secrete MCP-1, IL-6, IL-8, GCP-2, HGF, KGF, FGF, HB-EGF, BDNF, TPO, MIP1b, RANTES, and TIMP1; and

d) increased expression of endogenous genes encoding interleukin 8 and reticulon 1 relative to endogenous expression of interleukin 8 and reticulon 1 in a human cell that is a fibroblast, a mesenchymal stem cell, or an ileac crest bone marrow cell,

and wherein the scaffold comprising the umbilical cord tissue-derived cells stimulates cell infiltration into the soft tissue defect.

11. The method of claim 10 , wherein the umbilical cord tissue-derived do not secrete SDF-1alpha, TGF-beta2, ANG2, PDGFbb, MIP1a, and VEGF.

12. The method of claim 10 , wherein the soft tissue comprises blood vessels.

13. The method of claim 10 , wherein the step of administering comprises implanting, injecting, or engrafting the scaffold.

14. The method of claim 10 , wherein the scaffold is flat, tubular, or multilayered.

15. The method of claim 10 , wherein the scaffold comprises a nonwoven mat, a porous foam, a suture, or a hydrogel.

Continuity (6)
Continuation 15362453 · Nov 28, 2016
Continuation 11316104 · Dec 22, 2005
Continuation In Part 10877009 · Jun 25, 2004
Provisional Application 60638702 · Dec 23, 2004
Provisional Application 60483264 · Jun 27, 2003
Related Publication 20180338999A1 · Nov 29, 2018